Skip to Content

Drug interactions between acetaminophen / butalbital and BuSpar

Results for the following 2 drugs:
acetaminophen/butalbital
BuSpar (buspirone)

Interactions between your drugs

Moderate

busPIRone butalbital

Applies to: BuSpar (buspirone) and acetaminophen / butalbital

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of buspirone, which is primarily metabolized by the isoenzyme. Conversely, discontinuation of an inducer may increase buspirone plasma concentrations and increase the risk of central nervous system depression and other adverse effects. When a single 30 mg dose of buspirone was administered following treatment with the potent CYP450 3A4 inducer rifampin (600 mg once daily for 5 days) in 10 healthy volunteers, mean buspirone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately 84% and 90%, respectively, compared to administration following placebo. None of the subjects had a measurable plasma buspirone concentration at 6, 8 or 10 hours after given rifampin, while buspirone concentration could be determined up to 10 hours in all subjects after placebo. Pharmacodynamic effects of buspirone were also significantly reduced by rifampin in the study. Similar results were reported in another pharmacokinetic study conducted by the same group of investigators.

MANAGEMENT: The potential for diminished pharmacologic effects of buspirone should be considered during coadministration with CYP450 3A4 inducers. Pharmacologic response to buspirone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the buspirone dosage adjusted as necessary.

References

  1. Kivisto KT, Lamberg TS, Neuvonen PJ "Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone." Pharmacol Toxicol 84 (1999): 94-7
  2. "Product Information. Buspar (buspirone)." Bristol-Myers Squibb, Princeton, NJ.
  3. Lamberg TS, Kivisto KT, Neuvonen PJ "Concentrations and effects of buspirone are considerably reduced by rifampicin." Br J Clin Pharmacol 45 (1998): 381-5

Drug and food interactions

Moderate

busPIRone food

Applies to: BuSpar (buspirone)

You should avoid the use of alcohol while being treated with busPIRone. Alcohol can increase the nervous system side effects of busPIRone such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. Patients receiving busPIRone should preferably avoid the consumption of large amounts of grapefruits and grapefruit juice. If this is not possible, the busPIRone dose should be taken at least 2 hours before or 8 hours after grapefruit or grapefruit juice. Large amounts of grapefruit and grapefruit juice may cause increased levels of busPIRone in your body. This can lead to increased adverse effects such as drowsiness. Talk to your doctor or pharmacist if you have any questions or concerns.

Switch to professional interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Tranquilizers

Therapeutic duplication

The recommended maximum number of medicines in the 'tranquilizers' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'tranquilizers' category:

  • acetaminophen/butalbital
  • BuSpar (buspirone)

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide